Clinical trial

A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor

NCT05332574

Study summary

ClinicalTrials.gov

A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention GB263T Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-05-17

PhasePHASE1 / PHASE2

Conditions

NSCLCverified · MONDO: non-small cell lung carcinoma

Other Solid Tumorsunresolved

Interventions

GB263TBIOLOGICAL

Sponsors & collaborators

Genor Biopharma Co., Ltd.lead sponsor

Mapped research locations

MelbourneVictoria, Australia1 WestmeadNew South Wales, Australia1 MalvernVictoria, Australia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05332574 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.